News
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 diabetes patients.
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results